Deutsche Bank has reaffirmed its 'buy' rating on AJ Bell PLC, setting a target price of 700p due to robust growth in direct-to-consumer customers, which rose 7% quarter-on-quarter and 30% year-on-year in Q3. This growth is driven by effective marketing efforts, including a recent brand refresh, with the lifetime value of new customers exceeding acquisition costs. Deutsche Bank supports AJ Bell's strategy to increase marketing investment in 2027, balancing short-term profit margins around 40% with long-term revenue and profit growth potential. The bank views marketing spend as a short-term margin challenge that supports sustainable value creation.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
